RenovoRx’s IP Portfolio Grows, Drug-Delivery Platform Expands
RenovoRx (Nasdaq: RNXT) is bolstering its intellectual property (IP) portfolio with a new international patent application for its Trans-Arterial...
Jon Napitupulu
Sangamo Regains Full Rights to Hemophilia A Gene Therapy
Sangamo Therapeutics will regain control of giroctocogene fitelparvovec, a hemophilia A gene therapy candidate, after Pfizer terminated their collaboration...
Delcath Systems Secures $16.3M in Funding
Delcath Systems, Inc. secured $16.3 million in funding through the exercise of Series E and E1 warrants, with a...
Kala Bio’s $10.75M Private Placement: A Promising Opportunity?
Kala Bio, a clinical-stage biopharmaceutical company focused on eye diseases, secured approximately $10.75 million in a private placement involving...
Telix Pharma: Noble Registry Update: TLX599-CDX PSMA SPECT Imaging
Telix Pharmaceuticals and the Oncidium foundation announced positive initial results from the NOBLE Registry, a real-world evidence study of...
Beigene Tevibra Approved in US for Gastric Cancer Treatment
The FDA approved BeiGene‘s TEVIMBRA (tislelizumab-jsgr), combined with chemotherapy, for first-line treatment of advanced HER2-negative gastric or gastroesophageal junction...
Takeda Hyqvia 10% Injection Approved in Japan for Immunodeficiency
Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare for HYQVIA, a facilitated subcutaneous immunoglobulin...
Psyence Biomed Closes $2M Private Placement
Psyence Biomedical Ltd., a Nasdaq-listed biotechnology company (Nasdaq: PBM), recently finalized a private placement, raising approximately $2 million before...
Vor Bio Announces $55.6M Private Placement
Vor Bio, a clinical-stage cell and genome engineering company, has secured approximately $55.6 million in gross proceeds through a...
Ikena Oncology and Inmagene Merger Announcement
Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. The combined company will focus on developing...